In an interview with MedCity News on day three of the BIO International Convention, Ricks discussed his company's newly expanded R&D facility in San Diego, the challenges of drug discovery, and the ultimate reward.
Red blood cells tend to mind their own business, but what if they could be engineered to replace missing enzymes, activate T-cells, or bind tumor cells? It's an exciting possibility that has garnered a highly oversubscribed $120 million Series B.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
For all the complexity of CAR-T autologous transplant technology, GE Ventures spin-out Vineti has a simple question to ask: What if the wrong cells are infused back into the patient?
Despite reimbursement, regulatory, and political uncertainty, the global biotech industry held steady in 2016, according to a new report by professional services firm EY (formerly Ernst & Young).